We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Lumos Pharma Inc (LUMO) USD0.01

Sell:$6.75 Buy:$9.85 Change: $0.01 (0.13%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$6.75
Buy:$9.85
Change: $0.01 (0.13%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$6.75
Buy:$9.85
Change: $0.01 (0.13%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.

Contact details

Address:
4200 MARATHON BLVD., SUITE 200
AUSTIN
78756
United States
Telephone:
+1 (512) 2152630
Website:
https://lumos-pharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LUMO
ISIN:
US55028X1090
Market cap:
$64.36 million
Shares in issue:
8.37 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Hawkins
    Chairman of the Board, Chief Executive Officer
  • John McKew
    President, Chief Operating Officer, Chief Scientific Officer
  • Lori Lawley
    Chief Financial Officer, Principal Accounting Officer
  • Bradley Powers
    General Counsel
  • David Karpf
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.